M J Ellis

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial
    M J Ellis
    Duke University Breast Cancer Program, Duke University Comprehensive Cancer Center, Durham, NC 27710, USA
    J Clin Oncol 19:3808-16. 2001
  2. ncbi Neoadjuvant endocrine therapy for breast cancer: medical perspectives
    M J Ellis
    Duke University Breast Cancer Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 7:4388s-4391s; discussion 4411s-4412s. 2001
  3. ncbi Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect
    Matthew J Ellis
    Breast Cancer Program, DUMC, Duke University, PO Box 3446, Durham, NC 27710, USA
    J Steroid Biochem Mol Biol 86:301-7. 2003
  4. ncbi Chronic kidney disease after hematopoietic cell transplantation: a systematic review
    M J Ellis
    Division of Nephrology, Duke University Medical Center, Durham, NC, USA
    Am J Transplant 8:2378-90. 2008
  5. ncbi Breast cancer gene expression analysis--the case for dynamic profiling
    Matthew J Ellis
    Duke University Breast Cancer Program, Duke University Medical Center, DUMC PO Box 3446, Durham, NC 27710, USA
    Adv Exp Med Biol 532:223-34. 2003
  6. ncbi Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
    Matthew J Ellis
    Siteman Comprehensive Cancer Center, Washington University School of Medicine, Campus Box 8056, 660 S Euclid Ave, St Louis, MO 63110, USA
    J Clin Oncol 24:3019-25. 2006
  7. ncbi Neoadjuvant endocrine therapy for locally advanced breast cancer
    Cynthia X Ma
    Department of Oncology, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Semin Oncol 33:650-6. 2006
  8. ncbi Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data
    Matthew J Ellis
    Siteman Comprehensive Cancer Center and Washington University School of Medicine, St Louis, MO 63110, USA
    Curr Med Res Opin 22:2479-87. 2006
  9. ncbi Neoadjuvant endocrine therapy for breast cancer: more questions than answers
    Matthew J Ellis
    J Clin Oncol 23:4842-4. 2005
  10. ncbi Letrozole in the treatment of breast cancer
    Heather S Shaw
    Multidisciplinary Breast Program, Duke University Medical Center, Box 3381, Durham, NC 27710, USA
    Expert Opin Pharmacother 3:607-17. 2002

Collaborators

Detail Information

Publications33

  1. ncbi Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial
    M J Ellis
    Duke University Breast Cancer Program, Duke University Comprehensive Cancer Center, Durham, NC 27710, USA
    J Clin Oncol 19:3808-16. 2001
    ..A neoadjuvant study for primary breast cancer that randomized treatment between letrozole and tamoxifen provided a context within which these issues could be addressed prospectively...
  2. ncbi Neoadjuvant endocrine therapy for breast cancer: medical perspectives
    M J Ellis
    Duke University Breast Cancer Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 7:4388s-4391s; discussion 4411s-4412s. 2001
    ....
  3. ncbi Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect
    Matthew J Ellis
    Breast Cancer Program, DUMC, Duke University, PO Box 3446, Durham, NC 27710, USA
    J Steroid Biochem Mol Biol 86:301-7. 2003
    ..When enough profiles have been generated it should be possible to detect complex interaction patterns that correctly reclassify ER+ disease into treatment responsive and resistant categories with high probability...
  4. ncbi Chronic kidney disease after hematopoietic cell transplantation: a systematic review
    M J Ellis
    Division of Nephrology, Duke University Medical Center, Durham, NC, USA
    Am J Transplant 8:2378-90. 2008
    ....
  5. ncbi Breast cancer gene expression analysis--the case for dynamic profiling
    Matthew J Ellis
    Duke University Breast Cancer Program, Duke University Medical Center, DUMC PO Box 3446, Durham, NC 27710, USA
    Adv Exp Med Biol 532:223-34. 2003
    ..Using breast cancer endocrine therapy as an example our initial approaches to dynamic profiling will be described...
  6. ncbi Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
    Matthew J Ellis
    Siteman Comprehensive Cancer Center, Washington University School of Medicine, Campus Box 8056, 660 S Euclid Ave, St Louis, MO 63110, USA
    J Clin Oncol 24:3019-25. 2006
    ....
  7. ncbi Neoadjuvant endocrine therapy for locally advanced breast cancer
    Cynthia X Ma
    Department of Oncology, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Semin Oncol 33:650-6. 2006
    ..In this review, we outline the rationale for preoperative endocrine therapy, and consider predictive models for endocrine therapy responsiveness in this setting...
  8. ncbi Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data
    Matthew J Ellis
    Siteman Comprehensive Cancer Center and Washington University School of Medicine, St Louis, MO 63110, USA
    Curr Med Res Opin 22:2479-87. 2006
    ..This review will compare the current available efficacy, safety, and cost-effectiveness data for AIs in the initial adjuvant and switch adjuvant settings...
  9. ncbi Neoadjuvant endocrine therapy for breast cancer: more questions than answers
    Matthew J Ellis
    J Clin Oncol 23:4842-4. 2005
  10. ncbi Letrozole in the treatment of breast cancer
    Heather S Shaw
    Multidisciplinary Breast Program, Duke University Medical Center, Box 3381, Durham, NC 27710, USA
    Expert Opin Pharmacother 3:607-17. 2002
    ..The object of this review is to provide a reference source on the biochemical, pharmacological and clinical properties of letrozole for clinicians to consider both established and future indications...
  11. ncbi Letrozole in the neoadjuvant setting: the P024 trial
    Matthew J Ellis
    Medical Oncology, Washington University, Campus Box 8056, 660 Euclid Ave, St Louis, MO 63110, USA
    Breast Cancer Res Treat 105:33-43. 2007
    ..0009). Thus, neoadjuvant letrozole is safe and superior to tamoxifen in the treatment of postmenopausal women with HR+ locally advanced breast cancer...
  12. ncbi The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers
    P Kelly Marcom
    Siteman Comprehensive Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8056, St Louis, MO, USA
    Breast Cancer Res Treat 102:43-9. 2007
    ..The efficacy of the aromatase inhibitor letrozole in combination with trastuzumab was therefore tested in a Phase 2 study...
  13. ncbi Neoadjuvant endocrine therapy for breast cancer: an overlooked option?
    Zee-Wan Wong
    National Cancer Centre, Singapore
    Oncology (Williston Park) 18:411-20; discussion 421, 424, 429 passim. 2004
    ....
  14. ncbi Estrogen receptor expression and sensitivity to paclitaxel in breast cancer
    Michele K Dougherty
    Lombardi Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
    Cancer Biol Ther 3:460-7. 2004
    ..These data suggest that measurements of tumor proliferation may provide more accurate predictive markers for the benefits of adjuvant paclitaxel than ERalpha analysis...
  15. ncbi Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy
    Matthew J Ellis
    Washington University School of Medicine, Section of Medical Oncology and Breast Cancer Program, St Louis, Missouri, USA
    Ann Surg Oncol 11:9S-17S. 2004
    ..Ongoing investigations are examining gene expression profile changes associated with neoadjuvant endocrine therapy, as well as inhibitors of growth factor signaling that may modulate tamoxifen resistance...
  16. ncbi Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status
    Matthew J Ellis
    Duke University Comprehensive Cancer Center, Campus Box 8056, 660 South Euclid, Durham, NC 27710, USA
    Cancer Res 63:6523-31. 2003
    ....
  17. ncbi Neoadjuvant endocrine therapy as a drug development strategy
    Matthew J Ellis
    Washington University School of Medicine, St Louis, Missouri, USA
    Clin Cancer Res 10:391S-5S. 2004
    ..However, the optimal clinical investigative approaches, analytical techniques, and appropriate surrogate end points have yet to be identified and are the subject of several ongoing or planned clinical studies...
  18. ncbi Role of biologic markers in patient selection and application to disease prevention
    Mitch Dowsett
    Joint Institute of Cancer Research/Royal Marsden NHS Trust, Academic Department of Biochemistry, London, United Kingdom
    Am J Clin Oncol 26:S34-9. 2003
    ..Gene expression profiling (microarray analysis), i.e., genomic and proteomic studies, will probably advance the discovery of new biomarkers for breast cancer prevention and treatment...
  19. ncbi Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
    Matthew J Ellis
    Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63119, USA
    J Natl Cancer Inst 100:1380-8. 2008
    ....
  20. ncbi A luminal breast cancer genome atlas: progress and barriers
    Matthew J Ellis
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63119, USA
    J Steroid Biochem Mol Biol 106:125-9. 2007
    ....
  21. ncbi Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board
    Matthew J Ellis
    J Natl Cancer Inst 100:159-61. 2008
  22. ncbi "PIKing" the winner for phosphatidylinositol 3-kinase inhibitors in ErbB2-positive breast cancer: let's not "PTENed" it's easy!
    Matthew J Ellis
    Clin Cancer Res 13:5661-2. 2007
  23. ncbi HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
    ..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both...
  24. ncbi Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
    Daniel F Hayes
    Department of Internal Medicine and the Comprehensive Cancer Center, University of Michigan Health and Hospital System, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 12:4218-24. 2006
    ..In this study, additional follow-up data and CTC levels at subsequent follow-up visits were evaluated...
  25. ncbi Dramatic response of choroidal metastases from breast cancer to a combination of trastuzumab and vinorelbine
    Zee-Wan Wong
    National Cancer Center, Singapore
    Breast J 10:54-6. 2004
    ....
  26. ncbi Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:327S-330S. 2004
  27. ncbi Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 351:781-91. 2004
    ..We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer...
  28. ncbi Successful targeting of ErbB2 receptors-is PTEN the key?
    Robert J Crowder
    Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, Campus Box 8056, 660 South Euclid Avenue, St. Louis, MO 63110, USA
    Cancer Cell 6:103-4. 2004
    ..Resistance to trastuzumab occurs when PTEN function is lost, suggesting that PTEN activation is a critical component of the therapeutic effect...
  29. ncbi A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia
    Vered Stearns
    Breast Cancer Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C, USA
    Clin Cancer Res 10:7583-91. 2004
    ..Further investigations must overcome logistical obstacles to accrual, and they must focus on approaches to maximize tissue collection and to incorporate genomic analysis of target lesions...
  30. ncbi Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway
    Robert J Crowder
    Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, St Louis, Missouri, USA
    Breast Cancer Res 7:212-4. 2005
    ....
  31. ncbi Functional analysis of the breast cancer genome
    Matthew J Ellis
    J Clin Oncol 24:1649-50. 2006
  32. ncbi The molecular portraits of breast tumors are conserved across microarray platforms
    Zhiyuan Hu
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    BMC Genomics 7:96. 2006
    ..To overcome this problem we used publicly available breast cancer gene expression data sets and a novel approach to data fusion, in order to validate a new breast tumor intrinsic list...
  33. ncbi Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    Howard A Burris
    The Sarah Cannon Research Institute, 250 25th Avenue N, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 23:5305-13. 2005
    ....